Quarterly ResultMay 19, 2026, 04:07 PM
Iridex Q1 Revenue $11.8M; Net Loss Narrows to $0.5M
AI Summary
Iridex Corporation reported Q1 2026 financial results with total revenue of $11.8 million, a 1% decrease year-over-year. The company saw strong growth in its Cyclo G6 product family revenue, up 14% to $3.6 million, while retina product revenue declined due to international supply constraints. Operating expenses were reduced by 4%, leading to a significantly improved net loss of $0.5 million compared to $1.7 million in the prior year. Iridex reaffirmed its full-year 2026 revenue guidance of $51 million to $53 million and expects to generate positive operating cash flow for the fiscal year.
Key Highlights
- Iridex Q1 2026 total revenue was $11.8 million, down 1% YoY.
- Cyclo G6 product family revenue grew 14% YoY to $3.6 million.
- Retina product revenue decreased to $5.8 million from $6.6 million YoY.
- Operating expenses reduced by 4% YoY to $5.1 million.
- Net loss significantly improved to $0.5 million ($0.03 per share) from $1.7 million ($0.10 per share) YoY.
- Cash and cash equivalents were $4.6 million as of April 4, 2026.
- Reaffirmed 2026 annual revenue guidance of $51 million to $53 million.
- Expects positive operating cash flow for the full year 2026.
Price Impact
More from IRIX